Clinical Trials

Status Epilepticus Study

A study evaluating SCI-210 for the treatment of Status Epilepticus (SE), conducted at The Chaim Sheba Medical Center in Israel.

Study outcome

Positive

study results

December 2022: positive study results with SCI-210 for SE at The Chaim Sheba Medical Center in Israel.

Efficacy vs. CBD monotherapy

SCI-210

Investigational drug

The study concluded that SCI-210 treatment may potentially be more effective than CBD monotherapy.

Safety profile

Safer

Treatment

Concentrations used in the combination treatment were significantly lower than those recommended for CBD monotherapy, and the treatment therefore also has the potential to be safer.